Company intelligence / Profile preview

CapsoVision

Saratoga, California, United Statescapsovision.com ↗

Ownership: Private
Employees: ~90
Development stage: Commercial

Overview

CapsoVision’s flagship product, the CapsoCam Plus®, provides 360° panoramic imaging of the small bowel and has been commercially available in the U.S. since 2017. It recently received FDA clearance for pediatric use and remote ingestion at home. The company plans to add AI-assisted lesion detection and expand into colon imaging with its next-generation device[2][5][8]. Clinical literature supports higher lesion detection rates compared to traditional end-facing capsule systems[8].

Therapeutic areas: GastroenterologyOncology
Modalities: Device
Industry: Medical Imaging

Drug pipeline

1 asset

CapsoCam Plus

Commercial

Indications: Small bowel disorders, Gastrointestinal disorders

Beyond the preview

Go deeper on CapsoVision.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CapsoVision.

Explore the full profile